Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiangtangtiaogan is a Traditional Chinese Medicine (TCM) formula developed by researchers at Zhongda Hospital, Southeast University, for the treatment of type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD). Based on the TCM theory of "treating diabetes from the liver," the formula aims to harmonize liver function to regulate systemic glucose and lipid metabolism. It has been shown to improve insulin resistance, reduce hepatic steatosis, and alleviate systemic inflammation. Mechanistically, Jiangtangtiaogan modulates the PI3K/Akt signaling pathway in the liver and skeletal muscle and influences the gut microbiota-bile acid axis to improve metabolic homeostasis. It is typically administered as an oral decoction or in granule form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jiangtangtiaogan.